Evaluation of P16 expression in canine appendicular osteosarcoma

Research output: Contribution to journalArticle

Abstract

Background: Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy. Results: We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval. Conclusions: The identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.

Original languageEnglish (US)
Article number189
JournalBMC Veterinary Research
Volume13
Issue number1
DOIs
StatePublished - Jun 20 2017

Fingerprint

osteosarcoma
Osteosarcoma
Canidae
dogs
drug therapy
Dogs
Drug Therapy
neoplasms
tumor suppressor genes
amputation
dog breeds
Tumor Suppressor Genes
Amputation
metastasis
Neoplasms
lungs
bones
Neoplasm Metastasis
Bone and Bones
Lung

Keywords

  • Canine
  • Immunohistochemistry
  • Osteosarcoma
  • P16
  • Tissue microarray

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{b9dfe54e961f45a49a65d8ee517cd4e1,
title = "Evaluation of P16 expression in canine appendicular osteosarcoma",
abstract = "Background: Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy. Results: We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval. Conclusions: The identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.",
keywords = "Canine, Immunohistochemistry, Osteosarcoma, P16, Tissue microarray",
author = "Murphy, {Brian G} and Mok, {M. Y.} and Daniel York and Rebhun, {Robert B} and Woolard, {Kevin D} and C. Hillman and Dickinson, {Peter J} and Skorupski, {Katherine A}",
year = "2017",
month = "6",
day = "20",
doi = "10.1186/s12917-017-1113-5",
language = "English (US)",
volume = "13",
journal = "BMC Veterinary Research",
issn = "1746-6148",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluation of P16 expression in canine appendicular osteosarcoma

AU - Murphy, Brian G

AU - Mok, M. Y.

AU - York, Daniel

AU - Rebhun, Robert B

AU - Woolard, Kevin D

AU - Hillman, C.

AU - Dickinson, Peter J

AU - Skorupski, Katherine A

PY - 2017/6/20

Y1 - 2017/6/20

N2 - Background: Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy. Results: We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval. Conclusions: The identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.

AB - Background: Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than 1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed. In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy. Results: We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA P16 expression and a shorter disease free interval. Conclusions: The identification of a molecular marker for canine OSA is an important goal and the results reported here justify a larger study.

KW - Canine

KW - Immunohistochemistry

KW - Osteosarcoma

KW - P16

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=85020865933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020865933&partnerID=8YFLogxK

U2 - 10.1186/s12917-017-1113-5

DO - 10.1186/s12917-017-1113-5

M3 - Article

C2 - 28633676

AN - SCOPUS:85020865933

VL - 13

JO - BMC Veterinary Research

JF - BMC Veterinary Research

SN - 1746-6148

IS - 1

M1 - 189

ER -